Ovid Therapeutics
OVID
84 hedge funds and large institutions have $101M invested in Ovid Therapeutics in 2025 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 25 increasing their positions, 24 reducing their positions, and 13 closing their positions.
514% more call options, than puts
Call options by funds: $424K | Put options by funds: $69K
114% more capital invested
Capital invested by funds: $47.1M → $101M (+$53.5M)
54% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 13
4% more funds holding
Funds holding: 81 → 84 (+3)
4% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 24
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
3.47% less ownership
Funds ownership: 50.92% → 47.46% (-3.5%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$16.5M |
| 2 |
AAA
Affinity Asset Advisors
New York
|
+$6.93M |
| 3 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$6.6M |
| 4 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
+$6.58M |
| 5 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$5.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$1.82M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
-$1.62M |
| 3 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
-$1.44M |
| 4 |
IC
Ikarian Capital
Dallas,
Texas
|
-$1.31M |
| 5 |
SSA
Schonfeld Strategic Advisors
New York
|
-$1.06M |
OVID Hedge Fund Activity: Q4 2025 in Review
84 of the 8,270 institutional investors tracked by Wall St. Rank reported a position in Ovid Therapeutics (OVID) for Q4 2025, worth a combined $101M — up 114% from $47.1M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new OVID positions and 13 closed out — a net gain of 7 holders — while 25 added to existing stakes and 24 trimmed.
The largest buyer was RA Capital Management, opening a new position worth an estimated $16.5M. The largest seller was Driehaus Capital Management, exiting entirely with an estimated $1.82M sold.
- 84 institutional investors held Ovid Therapeutics (OVID) as of Q4 2025, up from 81 in Q3 2025.
- Funds reported $101M of Ovid Therapeutics stock for Q4 2025, up 114% quarter-over-quarter.
- 20 funds opened new Ovid Therapeutics positions in Q4 2025 and 13 closed out, a net change of +7 holders.
- The largest Ovid Therapeutics buyer in Q4 2025 was RA Capital Management, an estimated $16.5M added.
- The largest Ovid Therapeutics seller in Q4 2025 was Driehaus Capital Management, an estimated $1.82M sold.
Based on aggregated 13F filings for Q4 2025.